Angion Biomedica (ANGN) – Globe Newswire
-
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR
-
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
-
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
-
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
-
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
-
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
-
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
-
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
-
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
-
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
-
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
-
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
-
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
-
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
-
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
-
Angion Announces Participation in Upcoming Investment Conference
-
Angion Announces Participation in Upcoming Investment Conference
-
Angion Announces Participation in Upcoming Investment Conference
-
Angion Announces Participation in Upcoming Investment Conference
-
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
-
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
-
Angion Announces Participation in Upcoming Investment Conferences
-
Angion Announces Participation in Upcoming Investment Conferences
-
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
-
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
-
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
-
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
-
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
-
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
-
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
-
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
-
Angion to Participate in Upcoming Investment Conference
-
Angion to Participate in Upcoming Investment Conference
-
Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function
-
Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function
-
Angion to Present Multiple Posters at Kidney Week 2021
-
Angion to Present Multiple Posters at Kidney Week 2021
-
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
-
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
-
Angion to Participate in Upcoming September Investment Conferences
-
Angion to Participate in Upcoming September Investment Conferences
-
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
-
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Back to ANGN Stock Lookup
